Jiraganya Bhongsatiern1, Chris Stockmann, Jessica K Roberts, Tian Yu, Kent E Korgenski, Michael G Spigarelli, Pankaj B Desai, Catherine M T Sherwin. 1. *Department of Pharmaceutical Sciences, The James L. Winkle College of Pharmacy, University of Cincinnati, Ohio; †Division of Clinical Pharmacology, Department of Pediatrics, University of Utah School of Medicine; ‡Department of Pharmacology and Toxicology, University of Utah College of Pharmacy; and §Intermountain Healthcare, Pediatric Clinical Program, Salt Lake City, Utah.
Abstract
AIM: To develop a vancomycin population pharmacokinetic model and assess the probability of attaining a pharmacodynamic target associated with clinical and microbiological success, a ratio of the 24-hour area under the concentration-time curve to the minimum inhibitory concentration (MIC) ≥ 400, in a 5-year clinical cohort of preterm and term neonatal patients with late-onset staphylococcal sepsis. METHODS: Therapeutic drug monitoring data were obtained from septic neonates with ≥1 vancomycin concentration(s) from January 2006 to September 2011. Only neonates with a postnatal age of >72 hours and a positive microbiological culture were included. Population pharmacokinetic model was developed using nonlinear mixed effects modeling (NONMEM 7.2). Eleven demographic characteristics were evaluated as covariates. Probabilities of achieving the pharmacodynamic target were evaluated. RESULTS: A 1-compartment model with first-order elimination was constructed from 528 vancomycin concentrations collected from 152 preterm and term neonates. Body weight, creatinine clearance (CL), and postmenstrual age were identified as significant covariates. Estimated vancomycin CL and volume of distribution for typical neonates were 0.068 ± 0.03 L·h·kg and 0.62 ± 0.13 L/kg, respectively. Coagulase-negative staphylococci (85.5%) and Staphylococcus aureus (14.5%) were the common pathogenic organisms. The distribution of vancomycin MIC breakpoints was composed of approximately 70% MIC breakpoint of ≤2 mcg/mL. Approximately 54% of neonates, with a median serum creatinine concentration of 0.44 mg/dL, achieved the target ratio of 24-hour area under the concentration-time curve to the MIC ≥ 400 with a median daily dose of 30 (interquartile range, 21-42) mg/kg. CONCLUSIONS: Body weight, creatinine CL, and postmenstrual age significantly influenced vancomycin CL. The current vancomycin doses are acceptable at MICs ≤1 mcg/mL because they are likely to achieve the pharmacodynamic target in the majority of neonatal patients, although higher doses may be considered for more resistant staphylococcal infections.
AIM: To develop a vancomycin population pharmacokinetic model and assess the probability of attaining a pharmacodynamic target associated with clinical and microbiological success, a ratio of the 24-hour area under the concentration-time curve to the minimum inhibitory concentration (MIC) ≥ 400, in a 5-year clinical cohort of preterm and term neonatalpatients with late-onset staphylococcal sepsis. METHODS: Therapeutic drug monitoring data were obtained from septic neonates with ≥1 vancomycin concentration(s) from January 2006 to September 2011. Only neonates with a postnatal age of >72 hours and a positive microbiological culture were included. Population pharmacokinetic model was developed using nonlinear mixed effects modeling (NONMEM 7.2). Eleven demographic characteristics were evaluated as covariates. Probabilities of achieving the pharmacodynamic target were evaluated. RESULTS: A 1-compartment model with first-order elimination was constructed from 528 vancomycin concentrations collected from 152 preterm and term neonates. Body weight, creatinine clearance (CL), and postmenstrual age were identified as significant covariates. Estimated vancomycin CL and volume of distribution for typical neonates were 0.068 ± 0.03 L·h·kg and 0.62 ± 0.13 L/kg, respectively. Coagulase-negative staphylococci (85.5%) and Staphylococcus aureus (14.5%) were the common pathogenic organisms. The distribution of vancomycin MIC breakpoints was composed of approximately 70% MIC breakpoint of ≤2 mcg/mL. Approximately 54% of neonates, with a median serum creatinine concentration of 0.44 mg/dL, achieved the target ratio of 24-hour area under the concentration-time curve to the MIC ≥ 400 with a median daily dose of 30 (interquartile range, 21-42) mg/kg. CONCLUSIONS: Body weight, creatinine CL, and postmenstrual age significantly influenced vancomycin CL. The current vancomycin doses are acceptable at MICs ≤1 mcg/mL because they are likely to achieve the pharmacodynamic target in the majority of neonatalpatients, although higher doses may be considered for more resistant staphylococcal infections.
Authors: Karel Allegaert; Maike Kuppens; Djalila Mekahli; Elena Levtchenko; Florent Vanstapel; Christine Vanhole; John N van den Anker Journal: J Matern Fetal Neonatal Med Date: 2012-02-14
Authors: J N van den Anker; R de Groot; H M Broerse; P J Sauer; B J van der Heijden; W C Hop; J Lindemans Journal: Pediatrics Date: 1995-12 Impact factor: 7.124
Authors: Chris Stockmann; Michael G Spigarelli; Sarah C Campbell; Jonathan E Constance; Joshua D Courter; Emily A Thorell; Jared Olson; Catherine M T Sherwin Journal: Paediatr Drugs Date: 2014-02 Impact factor: 3.022
Authors: Jennifer Le; John S Bradley; William Murray; Gale L Romanowski; Tu T Tran; Natalie Nguyen; Susan Cho; Stephanie Natale; Ivilynn Bui; Tri M Tran; Edmund V Capparelli Journal: Pediatr Infect Dis J Date: 2013-04 Impact factor: 2.129
Authors: Michelle L Campbell; Dror Marchaim; Jason M Pogue; Bharath Sunkara; Suchitha Bheemreddy; Pradeep Bathina; Harish Pulluru; Neelu Chugh; Melanie N Wilson; Judy Moshos; Kimberley Ku; Kayoko Hayakawa; Emily T Martin; Paul R Lephart; Michael J Rybak; Keith S Kaye Journal: Ann Pharmacother Date: 2012-12-04 Impact factor: 3.154
Authors: Anouk van der Veen; Annemie Somers; Sophie Vanhaesebrouck; Rob Ter Heine; Roger Brüggemann; Karel Allegaert; Pieter De Cock Journal: Int J Clin Pharm Date: 2021-11-02
Authors: Domenico Umberto De Rose; Sara Cairoli; Marco Dionisi; Alessandra Santisi; Luca Massenzi; Bianca Maria Goffredo; Carlo Dionisi-Vici; Andrea Dotta; Cinzia Auriti Journal: Int J Mol Sci Date: 2020-08-17 Impact factor: 5.923